37 related articles for article (PubMed ID: 38442444)
1. Targeting bile salt homeostasis in biliary diseases.
Trampert DC; Kunst RF; van de Graaf SFJ
Curr Opin Gastroenterol; 2024 Mar; 40(2):62-69. PubMed ID: 38230695
[TBL] [Abstract][Full Text] [Related]
2. A novel model to study mechanisms of cholestasis in human cholangiocytes reveals a role for the SIPR2 pathway.
Islam D; Israr I; Taleb MAB; Rao A; Yosief R; Sultana R; Sampaziotis F; Tysoe OC; Trauner M; Karpen SJ; Ghanekar A; Kamath BM
Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38407207
[TBL] [Abstract][Full Text] [Related]
3. Dolomiaea souliei ethyl acetate extract protected against α-naphthylisothiocyanate-induced acute intrahepatic cholestasis through regulation of farnesoid x receptor-mediated bile acid metabolism.
Meng F; Zong W; Wei X; Tao Y; Wang G; Liao Z; Chen M
Phytomedicine; 2021 Jul; 87():153588. PubMed ID: 34091148
[TBL] [Abstract][Full Text] [Related]
4. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
Panzitt K; Jungwirth E; Krones E; Lee JM; Pollheimer M; Thallinger GG; Kolb-Lenz D; Xiao R; Thorell A; Trauner M; Fickert P; Marschall HU; Moore DD; Wagner M
J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
[TBL] [Abstract][Full Text] [Related]
5. Astragalus saponins protect against extrahepatic and intrahepatic cholestatic liver fibrosis models by activation of farnesoid X receptor.
Zhang L; Shi J; Shen Q; Fu Y; Qi S; Wu J; Chen J; Zhang H; Mu Y; Chen G; Liu P; Liu W
J Ethnopharmacol; 2024 Jan; 318(Pt A):116833. PubMed ID: 37400008
[TBL] [Abstract][Full Text] [Related]
6. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
7. Dehydrodiconiferyl alcohol, a lignan from Herpetospermum pedunculosum, alleviates cholestasis by activating pathways associated with the farnesoid X receptor.
Wei X; Ma Y; Dong Z; Wang G; Lan X; Liao Z; Chen M
Phytomedicine; 2021 Jan; 80():153378. PubMed ID: 33113499
[TBL] [Abstract][Full Text] [Related]
8. Baicalein alleviates intrahepatic cholestasis by regulating bile acid metabolism via an FXR-dependent manner.
Huang W; Qian Y; Lin J; Wang F; Kong X; Tan W
Biochem Biophys Res Commun; 2024 Apr; 705():149670. PubMed ID: 38442444
[TBL] [Abstract][Full Text] [Related]
9. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
10. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders.
Molinaro A; Marschall HU
Biochem Soc Trans; 2022 Feb; 50(1):361-373. PubMed ID: 35191955
[TBL] [Abstract][Full Text] [Related]
11. Role of farnesoid X receptor in cholestasis.
Yuan ZQ; Li KW
J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832
[TBL] [Abstract][Full Text] [Related]
12. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
